Arthneeti
All Q2 FY27 results →
HB

Hester Biosciences Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Hester Biosciences Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Price₹2,407
Market cap₹2.0K Cr
P/E38.6
Updated5 Nov 2026
Read3 min read

Get Hester Biosciences Ltd's next results in your feed

Hester Biosciences Ltd Q2 FY27 key numbers

Revenue
Poultry Healthcare Division Q2 revenue: INR 608.08 million, up 27% YoY.

As stated in Hester Biosciences Ltd's Q2 FY27 results statement · published 5 Nov 2026. Reported figures, not investment advice.

Based on Hester Biosciences Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). EBITDA (Standalone, Q2 FY27): INR 289.89 million, up 117% YoY.

From Hester Biosciences Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.

How did Hester Biosciences' revenue grow in the September 2026 quarter?

  • Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26).
  • Poultry Healthcare Division Q2 revenue: INR 608.08 million, up 27% YoY.
  • Animal Healthcare Division Q2 revenue: INR 220.67 million, up 34% YoY.

2 more points from Hester Biosciences Ltd's call on revenue

Create a free account to keep reading this call

What happened to Hester Biosciences' margins in Q2 FY27?

See what Hester Biosciences Ltd said on profitability & margins — free account, 30 seconds.

What capex is Hester Biosciences planning?

The presentation states the following regarding capex, capacity expansion, or new projects: - Capitalisation of BSL3 Laboratory and Fill Finish facility referenced, contributing to higher depreciation (Page 17, Standalone Profitability Analysis). - Capital expenditure during the six months ended 30 September 2026 was INR 42.07 million for Property, Plant and Equipment including capital advances and capital work-in-progress, reflecting ongoing investments (Pages 6, 11). - Unallocated assets comprising Property, Plant, and Equipment related to BSL-3 and Fill Finish facilities capitalised in the previous year intended to support multiple segments (Page 7).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Hester Biosciences raising money or cutting debt?

See what Hester Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Hester Biosciences' order book?

See what Hester Biosciences Ltd said on order book & pipeline — free account, 30 seconds.

Hester Biosciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.

Hester Biosciences Ltd Q2 FY27 results — key figures

Hester Biosciences Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue98
Operating profit (EBITDA)33
Operating margin33.4%
Profit before tax25
Net profit (PAT)21
EPS (₹)23.94

Source: Hester Biosciences Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹77 Cr, net profit ₹97 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Hester Bios's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Symbiotec Pharma (Q2 FY27)

    280 Cr, up 43% YoY from Rs. Key investor presentation takeaways from Symbiotec Pharmalab Ltd's Q2 FY27 investor presentation — and how it ranks against sector p

  • Glenmark Pharmaceuticals (Q2 FY27)

    42,473 million, down 29.8% YoY. Key investor presentation takeaways from Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation — and how it ranks against

  • Windlas Biotech (Q2 FY27)

    264 Cr, a 19% YoY increase from Rs. Key investor presentation takeaways from Windlas Biotech Ltd's Q2 FY27 investor presentation — and how it ranks against sect

  • Rubicon Research Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10). Key investor presentation takeaways

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Hester Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Hester Biosciences Ltd Q2 FY27 results?

Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). EBITDA (Standalone, Q2 FY27): INR 289.89 million, up 117% YoY.

What is Hester Biosciences Ltd share price analysis?

Hester Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 38.5 with a market cap of ₹2,048 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hester Biosciences Ltd planning capital expenditure?

The presentation states the following regarding capex, capacity expansion, or new projects:.

Keep Hester Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.